PROVE IT - TIMI 22

Protocol Design



** Revascularization includes only procedures occurring > 30d post randomization*

Cannon CP, Am Heart J 2002; 89:860-61

PROVE IT - TIMI 22

Lipid Results



Median LDL-C (Q1, Q3)
95 mg/dl (79, 113)
62 mg/dl (50, 79)

Note: Changes in LDL-C may differ from prior trials:

- **25% of patients on statins prior to ACS event**
- **ACS response lowers LDL-C from true baseline**

Cannon CP, N Engl J Med 2004; 350:1495-04

PROVE IT - TIMI 22

Lipid Results

DEATH, NON-FATAL MI, OR URGENT REVASCULARIZATION



Cannon CP, N Engl J Med 2004; 350:1495-04

PROVE IT - TIMI 22

Lipid Results

DEATH, NON-FATAL MI, OR URGENT REVASCULARIZATION AT *30 DAYS*



Cannon CP, N Engl J Med 2004; 350:1495-04

PROVE IT - TIMI 22

Lipid Results

Median C-reactive protein (hsCRP) levels by treatment



Ridker PM, J Am Coll Cardiol 2005; 45:1644-48

PROVE IT - TIMI 22

Lipid Results

Risk of Death or MI after Day 30



P=0.005 for prava
P=0.6 for atorva

Ridker PM, J Am Coll Cardiol 2005; 45:1644-48

PROVE IT - TIMI 22

Antibiotic Results



Cannon CP, N Engl J Med 2005; 352:1646-54